跳至主要内容
临床试验/NCT07335679
NCT07335679招募中不适用

Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma

University Hospital, Strasbourg, France1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年6月10日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60
试验地点
1
主要终点
Overall, specific, and progression-free survival in patients treated for adrenal cortical carcinoma (ACC)

研究概览

简要总结

Adrenal corticosteroid carcinoma (ACC) is a rare tumor of the adrenal cortex, with an estimated prevalence of 0.5 to 2 cases per million inhabitants per year.

Two peaks in incidence have been described: during the first decade of life and between 40 and 50 years of age, with a slight female predominance (female-to-male ratio of 1.5). The majority of cases (>90%) are sporadic, particularly in adults.

ACC may be discovered incidentally during an imaging examination performed for another reason (10 to 20% of cases) or in connection with a tumor syndrome (40-60% of cases) or hormonal hypersecretion (40 to 74% of cases). The diagnosis of CCS can be suggested by the combination of morphological characteristics seen on imaging and clinical and biological features (secretory syndrome), but only histopathology allows for a definitive diagnosis. Furthermore, histopathology enables the assessment of aggressiveness criteria (Weiss score, Ki67), which will influence further management and prognosis.

Given that CCS is a rare tumor, the investigators aim to study the clinical, biological, morphological, and histological characteristics and evaluate the prognosis of patients treated at our center in order to better understand the natural history of CCS and improve patient management.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult subject (≥ 18 years old)
  • Subjects followed at Strasbourg University Hospital for adrenal cortical carcinoma diagnosed between January 1, 2000, and May 31, 2025

排除标准

  • - Tumor reclassified as non-SCC by histopathology

结局指标

主要结局

Overall, specific, and progression-free survival in patients treated for adrenal cortical carcinoma (ACC)

时间窗: Up to 12 months

Overall survival: Is how long patients live after being diagnosed or treated, regardless of the cause of death. Example: If 100 patients are treated for ACC and 60 are alive after 5 years, the 5-year overall survival is 60%. It counts everyone, whether they die from ACC or something else, like an accident or another illness.

次要结局

未报告次要终点

研究者

发起方
University Hospital, Strasbourg, France
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验